Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Durvalumab and Tremelimumab for Pediatric Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand

cancer
lymphoma
durvalumab
acute leukemia
leukemia
  • 15 views
  • 08 Aug, 2022
  • 22 locations
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD-3)

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma

TACE
measurable disease
  • 0 views
  • 10 Jul, 2022
  • 7 locations
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus

cancer
liver cancer
systemic therapy
sorafenib
durvalumab
  • 445 views
  • 22 Jul, 2022
  • 16 locations
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC

  • 286 views
  • 10 Jul, 2022
  • 17 locations
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)

durvalumab and tremelimumab can improve Disease Free Survival (DFS) or Overall Survival (OS) compared to the current global standard-of-care (active monitoring). At the start of recruitment, patients with

neutrophil count
metastasis
nephrectomy
tremelimumab
ct scan
  • 60 views
  • 14 Feb, 2022
  • 35 locations
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

improvement in disease progression-free survival with dual Tremelimumab and Durvalumab treatment.

  • 1 views
  • 10 Feb, 2022
  • 1 location
TheraSphere With and Without Durvalumab and Tremelimumab for HCC (ROWAN)

The objective of the ROWAN clinical study is to assess the durability of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab, compared to those

neutrophil count
platelet count
metastasis
serum bilirubin
measurable disease
  • 0 views
  • 28 Jul, 2022
  • 1 location
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

in conjunction with SBRT or Durvalumab + Tremelimumab in conjunction with SBRT in patients with metastatic squamous cell carcinoma of head and neck, lung, or esophagus.

liver metastasis
neutrophil count
head and neck carcinoma
metastatic cancer
metastatic squamous cell carcinoma
  • 4 views
  • 05 Aug, 2021
  • 1 location
Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD)

Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and Durvalumab in combination with radiotherapy as first-line therapy. 2-arm, randomized, multicenter, phase II. Step 1 is Registration

metastasis
durvalumab
  • 1 views
  • 14 Feb, 2022
  • 1 location
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

> Durvalumab Tremelimumab Radiation Therapy

metastasis
tremelimumab
biliary tract cancer
cholangiocarcinoma
ascites
  • 23 views
  • 03 Mar, 2022
  • 1 location